Table 1

Summary of BRAF inhibitor trials

Trial

Patients

RR%

PFS

(months)

OS

(years)

Number

(Patients)

Summary


Phase 2

Ribas et al. [15]

Vemurafenib in previously treated metastatic melanoma

52

6.2

Not yet reached

132

Met primary end point of best overall survival target of 30% (95% CI: 43 to 61%)

Phase 3

Chapman et al. [16]

Vemurafenib

versus

dacarbazine in untreated metastatic melanoma

48

v

5

5.3

v

1.6

Not yet reached

675

Compared vemurafenib and dacarbazine with co-primary endpoints of overall survival and progression free survival.

84% vs 64% OS at 6 months (95% CI: 78 to 89)


OS, overall survival; PFS, progression free survival; RR, response rate.

Finn et al. BMC Medicine 2012 10:23   doi:10.1186/1741-7015-10-23

Open Data